• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

17.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Unlocking the Growth Potential of NASDAQ:AMPH. ↗
January 23, 2024
Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. 
Via Chartmill
News headline image
What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition ↗
January 19, 2024
Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion... 
Via Benzinga
News headline image
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' ↗
January 17, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. 
Via Benzinga
News headline image
NASDAQ:AMPH is not too expensive for the growth it is showing. ↗
January 17, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:AMPH. 
Via Chartmill
News headline image
Cassava Sciences Stock Continues Showing Rising Relative Strength ↗
January 16, 2024
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Why NASDAQ:AMPH is Poised for High Growth. ↗
January 16, 2024
Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics. 
Via Chartmill
News headline image
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. ↗
January 02, 2024
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
News headline image
Should you consider NASDAQ:AMPH for growth investing? ↗
December 26, 2023
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing? 
Via Chartmill
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
Via ACCESSWIRE
News headline image
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study ↗
December 28, 2023
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. 
Via Investor's Business Daily
News headline image
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher ↗
December 26, 2023
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. 
Via Investor's Business Daily
News headline image
Why NASDAQ:AMPH qualifies as a high growth stock. ↗
December 12, 2023
Why the growth investor may take a look at AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH). 
Via Chartmill
News headline image
Exploring NASDAQ:AMPH's CANSLIM characteristics. ↗
December 05, 2023
Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing? 
Via Chartmill
News headline image
Exploring growth characteristics of AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH). ↗
November 21, 2023
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. 
Via Chartmill
News headline image
3 Reasons Why Amphastar Is a Great Growth Stock ↗
December 26, 2023
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great... 
Via Talk Markets
News headline image
3 Stocks at the Forefront of Medical Innovation ↗
December 25, 2023
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. 
Via InvestorPlace
News headline image
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗
December 21, 2023
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. 
Via Investor's Business Daily
News headline image
TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗
December 07, 2023
TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93. 
Via Investor's Business Daily
News headline image
These Three Biotech Stocks Are Trading At A Discount ↗
November 23, 2023
Investors exposed to the biotech sector have seen mixed results this year. 
Via Talk Markets
News headline image
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
November 20, 2023
Via ACCESSWIRE
News headline image
Evaluating NASDAQ:AMPH for Growth Investment Opportunities. ↗
November 14, 2023
High growth, ROE and relative strength for AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), growth investors may appreciate this. 
Via Chartmill
News headline image
Recap: Amphastar Pharma Q3 Earnings ↗
November 08, 2023
 
Via Benzinga
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
November 08, 2023
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade ↗
November 10, 2023
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. 
Via Investor's Business Daily
News headline image
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 09, 2023
Via ACCESSWIRE
News headline image
7 Healthcare Stocks That Are Poised to Become the Next Unicorns ↗
November 09, 2023
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
News headline image
Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday ↗
November 09, 2023
U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Earnings Preview For Amphastar Pharma ↗
November 07, 2023
 
Via Benzinga
News headline image
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗
November 08, 2023
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap